Randomized Phase Ii Study Of Erlotinib (Erl) In Two Different Schedules With Concomitant Modified Xelox In The First-Line Treatment Of Metastatic Colorectal Cancer (Mcrc): Correlation With Serial Serum Levels Of Amphiregulin (Amr) And Transforming Growth Factor Receptor-Alpha (Tgfa)